IMMUNOASSAY FOR GLYCOSYLATED HEMOGLOBIN

促进糖尿病的诊断和管理 测量患者血清中的糖化血红蛋白。 这种分子的相对水平在糖尿病患者中升高， 病人 这些测量的现有方法 是耗时的并且需要相当多的技术专长。 在这里提出的工作中，我们计划产生单克隆抗体。 对糖基化蛋白上的糖基化残基具有特异性的抗体 血红蛋白。 这将通过免疫小鼠三 不同类型的免疫原：纯化的糖化血红蛋白， 从糖化血红蛋白衍生的肽，然后 与免疫原性载体蛋白偶联，并纯化 与脂质结合的糖肽。 这些将被注入 与多种佐剂协同作用以产生鼠 分泌单克隆抗体的杂交瘤， 区分两种血红蛋白。 这些抗体将 用于开发用于测量糖基化的“夹心”ELISA， 患者样本中的血红蛋白。 在II期研究中， 将完成该检测试剂盒的开发、优化和 使用临床材料进行验证和评价。

Diagnosis and management of diabetes melitus is facilitated measurements of glycosylated hemoglobin in patient serum. Relative levels of this molecule are elevated in the diabetic patient. The presently available methods for these measurements are time consuming and require considerable technical expertise. In the work proposed here, we plan to generate monoclonal antibodies specific for the glycosylated residue on glycosylated hemoglobin. This will be accomplished by immunizing mice three different types of immunogen: purified glycosylated hemoglobin, peptides derived from glycosylated hemoglobin and then conjugated to immunogenic carrier proteins, and purified glycopeptides conjugated to lipids. These will be injected in concert with a variety of adjuvants to generate murine hybridomas secreting monoclonal antibodies capable of distinguishing the two forms of hemoglobin. These antibodies will be used to develop a "sandwich" ELISA for measuring glycosylated hemoglobin in patient samples. In Phase II studies, the development of this assay will be completed, optomized and validated, and evaluated using clinical material.